Exagen is a medical technology company that designs and commercializes diagnostic testing products under the AVISE® brand to help rheumatologists diagnose, monitor, and predict outcomes in patients with complex autoimmune and rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis. The company's primary offering is AVISE® CTD, a blood test that incorporates proprietary biomarker technology and is performed in the company's own CLIA-certified laboratory, alongside complementary tests for specific conditions and disease monitoring. Revenue is generated through third-party insurance reimbursement and client billing, with the business targeting the approximately 6,000 U.S. rheumatologists who manage a large patient population with suspected autoimmune disease. Exagen continues to expand its test menu, develop new biomarkers for unmet clinical needs, and enhance the clinical utility of its existing platform through proprietary research and academic partnerships.